Original Medicare and Part C should provide a comprehensive pulmonary rehabilitation program for a person who has chronic issues with breathing. Original Medicare includes Part A, which is ...

Symptoms of some of the diseases that mimic lung cancer, such as asthma or acid reflux, are common with many conditions. They can include persistent cough, chest pain, shortness of breath, unexplained ...

Sometimes, lung cancer comes back after you’ve had treatment. This is called a recurrence. It can happen at any time or not at all. But lung cancer is most likely to return within 5 years after ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

The aim of this study was to generate and validate a numerical score for grading chest x-ray (CXR) severity and predicting response to treatment in adults with smear-positive pulmonary TB. Methods At ...

Background Recent evidence showed that 50% of chronic obstructive pulmonary disease (COPD) may be attributable to air pollution. We aimed to investigate the association between long-term air pollution ...

1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria ...

Hamartomas, about whose etiology little is known, show a uniform distribution throughout the middle decades. With asymptomatic pulmonary lesions it is universally recognized that few diagnostic ...

Common anticancer drugs may offer new hope to PTEN Hamartoma Tumour Syndrome patients. ScienceDaily . Retrieved April 17, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250331122120.htm ...

From the clinical perspective, these disorders are grouped under the umbrella of the PTEN Hamartoma Tumor Syndrome (PHTS), producing a highly heterogenic spectrum of effects on patients yet to be ...

If it lands in the lungs, it’s called a pulmonary embolism. Estimates vary widely, but according to the American Lung Association, around 900,000 U.S. adults experience this type of potentially ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese ...